

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PG3602USW	
Applicant(s): Campbell et al.					
Serial No. 09/830,836	Filing Date May 1, 2001	Examiner B. Robinson		Group Art Unit 1625	
Invention: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS					
<u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	20 -	31 =	0	x \$18.00	\$0.00
INDEP. CLAIMS	5 -	5 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<p><input checked="" type="checkbox"/> No additional fee is required for amendment.</p> <p><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed.</p> <p><input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.</p> <p><input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392 A duplicate copy of this sheet is enclosed.</p> <p><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.</p> <p><input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</p>					
 <i>Lorie Ann Morgan</i> <i>Signature</i> <i>Dated: 11 Sep 2002</i>					
<p>Lorie Ann Morgan, Reg. No. 38,181 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8222 Facsimile: (919) 483-7988</p>					
<div style="border: 1px solid black; padding: 5px;"> <p>I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.</p> </div>					
<div style="border: 1px solid black; padding: 5px;"> <p><i>Signature of Person Mailing Correspondence</i></p> </div>					
<div style="border: 1px solid black; padding: 5px;"> <p><i>Typed or Printed Name of Person Mailing Correspondence</i></p> </div>					

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on 9/11/02
Date

Allyson K. Jacobs
Signature

Allyson K. Jacobs
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify
each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1415
ja
10/23/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

I. Campbell et al.,

Serial No.: 09/830,836

Examiner: B. Robinson

Filing Date: 1 May 2001

Art Unit: 1625

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Commissioner of Patents
Washington D.C. 20231

SUPPLEMENTAL RESPONSE

Sir:

Further to the Office Action mailed 15 May 2002 and the response filed 13 August 2002, please amend and reconsider the instant application in view of the following amendments and remarks.

Amendment

In the Claims:

Please cancel claims 13 and 24. Please amend claims 1, 6, 8-10, 14, 18-23, 25-26 and 28-29 as follows. The following clean claims reflect the amendments being made herein. The following is a complete set of claims as pending after the instant amendment. A marked-up copy of the amended claims is attached hereto.